Plasmap is showing strong performance. Following certifications in the US, Europe, Japan, and Eurasia, the acquisition of China’s CVC certification is expected to accelerate its entry into overseas markets, which appears to be influencing the stock price.
As of 11:31 AM on the 6th, Plasmap is trading at 8,300 KRW, up 8.78% from the previous trading day.
Bio plasma deep-tech company Plasmap announced that its medical implant surface treatment device (ACTILINK) has obtained China’s CVC certification (Certainty Value-added Credibility). ACTILINK is a surface treatment device for implants that removes hydrocarbon impurities attached to the surface of bio-implants and sterilizes them. It is expected to maximize synergy as a comprehensive plasma care solution along with the low-temperature sterilization solution (STERLINK) for surgical instruments used in dentistry and the surface treatment solution ACTILINK for implants and prosthetics.
The CVC certification is a self-certification in China that proves a product’s quality, safety, environmental protection, and performance meet relevant standards. It is known for its strictness as it includes product safety evaluation and factory inspection. Obtaining this certification guarantees the product’s quality and consumer safety.
Plasmap’s surface treatment, which obtained the CVC certification, is the world’s first technology that efficiently generates plasma in a vacuum environment through atmospheric exhaust to remove impurities from the implant surface while enhancing surface energy, thereby improving implant performance. Plasmap’s independently developed plasma surface treatment technology has received New Technology Certification (NET) from the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. Along with rapid product development, it also acquired New Excellent Product (NEP) certification from the Ministry of Trade, Industry and Energy.
To accelerate overseas business, Plasmap received performance and reliability certification from the German Cleanimplant Foundation. Subsequently, it obtained European CE, Japanese VCCI, and Eurasian EAC certifications. With the acquisition of China’s CVC certification, Plasmap is proving its excellent technological capabilities and speeding up global commercialization.
Plasmap CEO Lim Yu-bong stated, “From the product development planning stage, we have been deriving requirements and promoting commercialization with consideration for entry into overseas markets,” adding, “Global certification acquisition is achievable.”
He continued, “We are expanding the rapidly growing implant surface treatment technology in the global dental market into the orthopedic market,” and added, “We will increase the technological gap and lead the market.”
Earlier, in early last month, Plasmap signed an MOU with the University of California, Los Angeles (UCLA) to jointly conduct clinical evaluation research utilizing Plasmap’s sterilization and surface treatment technologies. The clinical evaluation research at UCLA titled ‘Correlation between surface adhesion of medical implant materials, hydrocarbon reduction, and bacterial biofilm growth’ will use Plasmap’s low-temperature plasma sterilization solution and vacuum plasma medical implant surface treatment solution technology. It is expected that efforts to strengthen unique technological competitiveness across the entire value chain, from materials used in orthopedics to products, will accelerate.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
